Oliver Barnes(@mroliverbarnes) 's Twitter Profileg
Oliver Barnes

@mroliverbarnes

US pharma & biotech correspondent @FT 📩 [email protected]

ID:765541344295223296

linkhttps://www.ft.com/oliver-barnes calendar_today16-08-2016 13:30:54

9,9K Tweets

13,4K Followers

6,3K Following

Anna Nicolaou(@annaknicolaou) 's Twitter Profile Photo

new: Taylor is back on TT, just before the release of a new album, in a move that defies her own record label Universal (who has been at war w/TT for months)
she's can do this bc she owns her masters + publishing, unlike many other pop stars.
more here:
ft.com/content/79b8ac…

account_circle
Matthew Garrahan(@MattGarrahan) 's Twitter Profile Photo

NEW: Rishi Sunak quipped 'where's my office?' when he appeared at a groundbreaking for a new Blackstone operation in London.

Is he thinking about his next move after the election?

Story below 👇

ft.com/content/4c8222…

account_circle
Amesh Adalja(@AmeshAA) 's Twitter Profile Photo

“The demand in Africa for Covid-19 vaccines has declined since the pandemic and is insufficient to support the viability of the factory” ft.com/content/dbcce8…

account_circle
Ian Johnston(@ian_c_johnston) 's Twitter Profile Photo

After US crackdowns on TikTok and Huawei comes action against WuXi, a key supplier to pharma companies.

Drugmakers race to find alternative suppliers as US cracks down on Chinese biotech

on.ft.com/3xARLnK via @financialtimes

account_circle
Sense Hofstede(@sehof) 's Twitter Profile Photo

Western drugmakers race to find alternative suppliers as US cracks down on Chinese biotech – FT: ‘The bill labels Shanghai-based WuXi AppTec “a biotechnology company of concern”’ ft.com/content/bfe487…

account_circle
Simon Williams(@drsimonwilliams) 's Twitter Profile Photo

not good news. We still have significant vaccine inequalities globally

(low-middle-income countries vaccine coverage still much too low; many people still vulnerable within these populations to covid - acute infection and long)

account_circle
Drew Armstrong(@ArmstrongDrew) 's Twitter Profile Photo

One of the rare biotech pivots that paid off. Alpine started in oncology/cell therapy, going after CD28 -- then ended the program after two patient died. They flipped to ALPN-303, now called povetacicept, and now they've done a $4.9B deal with Vertex:

endpts.com/vertex-strikes…

account_circle
Bill Ackman(@BillAckman) 's Twitter Profile Photo

A front page The New York Times must read story on Multiplan and United Healthcare.

Our healthcare system is fundamentally corrupt and Multiplan and United Healthcare are exhibit A.

nytimes.com/2024/04/07/us/…

account_circle